CD8A and neoplasm: In an analysis of CheckMate-010 phase II trial, CD8+PD-1+TIM-3-LAG-3- tumor infiltrating cells were associated with a high level of T cell activation, a longer median immune related PFS and a higher immune related ORR to nivolumab[89].